Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACSL1 | P33121 | 2/20 | 0.45 |
| ▸ | ACSL6 | Q9UKU0 | 2/20 | 0.45 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.43 |
| ▸ | PPARA | Q07869 | 4/20 | 0.42 |
| ▸ | PPARG | P37231 | 3/20 | 0.41 |
| ▸ | PPARD | Q03181 | 3/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2511686 | 0.96 | ACSL1 (0.49) | ACSL1ACSL6KCNA3TSHRFFAR4 | |
| SCHEMBL9423929 | 0.83 | ACSL1 (0.50) | ACSL1ACSL6KCNA3TSHRFFAR4 | |
| SCHEMBL27694186 | 0.76 | L3MBTL1 (0.45) | TSHR | |
| SCHEMBL23091409 | 0.74 | KCNA3 (0.42) | KCNA3FFAR1PPARAPPARGPPARD | |
| SCHEMBL23091410 | 0.74 | KCNA3 (0.42) | KCNA3FFAR1PPARAPPARGPPARD | |
| SCHEMBL15237264 | 0.73 | GAA (0.56) | — | |
| SCHEMBL9170332 | 0.72 | ALOX5 (0.47) | ACSL1ACSL6TSHRFFAR4FFAR1 | |
| SCHEMBL9423885 | 0.72 | MAOA (0.51) | TSHRFFAR1PPARGPPARD | |
| SCHEMBL6566874 | 0.70 | L3MBTL1 (0.50) | — | |
| SCHEMBL2277251 | 0.70 | MAOB (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080227809-A1 | Arylalkylamine Vanadium (V) Salts for the Treatment and/or Prevention of Diabetes Mellitus | GENMEDICA THERAPEUTICS SL (ES) | 2008-09-18 | — | — | US | disclosed |
| EP-1765765-A1 | ARYLALKYLAMINE VANADIUM (V) SALTS FOR THE TREATMENT AND/OR PREVENTION OF DIABETES MELLITUS | Genmedica Therapeutics SL (ES) | 2007-03-28 | — | — | EP | disclosed |
| US-20070066682-A1 | Arylalkylamine vanadium (V) salts for the treatment and/or prevention of Diabetes mellitus | GENMEDICA THERAPEUTICS SL (ES) | 2007-03-22 | — | — | US | disclosed |
| WO-2006003189-A1 | ARYLALKYLAMINE VANADIUM (V) SALTS FOR THE TREATMENT AND/OR PREVENTION OF DIABETES MELLITUS | GENMEDICA THERAPEUTICS SL (ES) | 2006-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066682-A1 | Arylalkylamine vanadium (V) salts for the treatment and/or prevention of Diabetes mellitus | GPR119, ABCC1, INSR | ACSL1 1558/4885ACSL6 1644/4885KCNA3 50/4885 |
| US-20080227809-A1 | Arylalkylamine Vanadium (V) Salts for the Treatment and/or Prevention of Diabetes Mellitus | SLC5A1, GPR119, IAPP | ACSL1 1598/4885ACSL6 2363/4885KCNA3 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.